Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs Tesla, Inc. (TSLA) Price & Performance

Royalty Pharma plc Class A Ordinary SharesTrade

Tesla, Inc.Trade

Price performance (Past 24H)

Key statistics

Royalty Pharma plc Class A Ordinary Shares vs Tesla, Inc. — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B), while Tesla, Inc. trades at $379.35 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 59× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and Tesla, Inc. for 88 Days on average.

	RPRX	TSLA
Market Cap	$25.27B	$1.49T
Volume	3,671,183	25,496,215
Sector	Health	Consumer Cyclical
52-Week High	$63.96	$489.88
52-Week Low	$35.44	$298.16
Typical Hold Time	0 Days	88 Days
Enterprise Value	$32.50B	$1.46T
Dividend Yield	1.66%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Royalty Pharma plc Class A Ordinary Shares

No Aura AI signal available yet.

Tesla, Inc.

Tesla (TSLA) trades at $377.61, down 0.81% amid mixed signals. Technical analysis shows a bullish trend with key support at $375, while fundamentals reveal high valuation multiples (P/E 349.82) despite recent earnings beats. The company faces margin compression with net income declining to $3.79B in 2025. Recent news highlights regulatory approval for driver-assistance software in Europe (Reuters, 2026-04-10) and a potential cheaper EV model launch.

Tesla's investment case balances innovation leadership against valuation concerns. Upside potential exists from autonomous driving advances and energy/robotics growth, but risks include intense EV competition and execution challenges. Analysts maintain a cautious stance with 41% buy ratings and a $441.36 consensus target, suggesting modest upside from current levels.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RPRX

100% Buy0% Sell

Avg holding period · 0 Days

TSLA

16% Buy84% Sell

Avg holding period · 88 Days

Top news

Latest headlines on both assets

RPRX

View details →

TSLA

ARK Invest's AI bets focus on agent builders, trimming Robinhood shares despite CEO's 'follow the agents' advice.24/7 Wall Street · 15 hours agoNeutral Tesla's 2027 growth hinges on autonomy and AI, with $600 stock a stretch but possible.24/7 Wall Street · 23 hours agoNeutral Tesla stock expected to rise up to 33% as it shifts focus to AI and robotics, says Wall Street analysts.Finbold · 23 hours agoBullish View details →

About Royalty Pharma plc Class A Ordinary Shares

Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.

About Tesla, Inc.

Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.